Skip to content
Peptigraph home

Efinopegdutide Phase 2 trial (NCT04944992)

A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
145
actual
Start
4 Aug 2021 (actual)
Primary completion
19 Oct 2022 (actual)
Sponsor
Merck Sharp & Dohme LLC
Design

Arms and doses

NCT04944992 study arms
ArmTypeInterventionsDescription
EfinopegdutideExperimentalDrug: Efinopegdutide 20 mg/mLEfinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
SemaglutideActive comparatorDrug: Semaglutide 1.34 mg/mLSemaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.
Endpoints

Primary endpoint

NCT04944992 primary outcomes
MeasureTime frame
Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 WeeksBaseline and up to ~24 Weeks
Percentage of Participants Who Experienced an Adverse Event (AE)Up to ~29 weeks
Percentage of Participants Who Discontinued Study Intervention Due to an AEUp to ~24 weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04944992 secondary outcomes
MeasureTime frame
Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 WeeksBaseline and up to ~24 Weeks
Mean Percent Change From Baseline in Body Weight After 24 WeeksBaseline and up to ~24 weeks
Mean Percent Change From Baseline in Total Cholesterol After 24 WeeksBaseline and up to ~24 weeks
Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 WeeksBaseline and up to ~24 weeks
Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 WeeksBaseline and up to ~24 weeks
Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 WeeksBaseline and up to ~24 weeks
Mean Percent Change From Baseline in Triglycerides (TG) After 24 WeeksBaseline and up to ~24 weeks
Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 WeeksBaseline and up to ~24 weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
70 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04944992.

Liver fat results posted against semaglutide

The registry's first primary outcome is the relative reduction in liver fat content by MRI-PDFF after 24 weeks.[1]

The posted mean relative liver fat reduction was 72.7% for the efinopegdutide group and 42.3% for the semaglutide group.[1]

The posted difference in least-squares means was 30.4 percentage points, with a 90% interval of 22.1 to 38.7.[1]

The posted share of participants with any adverse event was 88.9% for efinopegdutide and 72.6% for semaglutide.[1]

Sources

  1. 1A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.